Lots of excellent abstracts at #ACR21 on assessment & impact of #comorbidities & #multimorbidity in RA, some discussed in this article @RheumNow: https://t.co/WXgv1GmHD6 Featured abstracts: #0798 https://t.co/02BRqYp9Yk #1450 https://t.co/iG2s2Cy8Q0 #1924 https://t.co/qHws6ALENH

• Towards better assessment and management of multimorbidity | RheumNow
• The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its…
• Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-…
• Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utiliza…

Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT designs to treat pts MORE likely to respond. Also for an individual, following ANCA is not that helpful for altering Rx Take a look at this session GS401 #ACR21 #ACRBest @RheumNow https://t.co/nrapO9i4gw

Abst 0478 Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand OA - Identified 5 Phenotypes - Symptoms correlated with metabolic syndrome, joint destruction & physical and psychological burden #ACR21 @RheumNow https://t.co/O9hweqNIS8

Bimekizumab (IL-17A and IL-17Fi) 3 year safety and efficacy in PsA Phase IIb trial ⭐️no new safety signals ⭐️candida infections were all mild/moderate ⭐️efficacy consistent and maintained Abs#491 #ACR21 @RheumNow https://t.co/BK6xPMqAEM https://t.co/meoPd7k0Xp

• Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylit…

Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at

More from Dr. Atul Deodhar on treatment of axSpA and axPsA. Guselkumab studies DISCOVER 1 & 2 looked at PsA with sacroiliitis and demonstrated improved measures of axial activity, but we need more studies and to include MR imaging. #ACR21 6S403 session @RheumNow https://t.co/8jM5Fj8MuD

Abst 0370 #ACR21 @rheum survey of PCPs reveals lack of awareness about inflammatory back pain: 58%never/rarely assess for IBP; 40% not comfortable with making the dx of IBP. 83%never/rarely ordered HLAB27, 65% never/ rarely ordered CRP, 72% rarely/never ordered X-ray SI joint

New therapies this year in rheumatology #ACR21 year in review Avacopan in AAV and Voclosporin in Lupus nephritis @RheumNow @karen_kc123 https://t.co/8Z28STMJ6X

Using machine learning to predict knee cartilage worsening over 2 years sing gait and physical activity using the MOST study #abst0210 #ACR21 @RheumNow https://t.co/0MAjLhpL7t

Overlap between RA and SLE: is the famous rhupus more frequent than it seems? In the Boston OM1 SLE Registry w/ 44,186 SLE: 4.7% also reported as having RA. This is higher than the usual reported prevalence. #ACR21 #Abst0354 @RheumNow https://t.co/FYfvSdCkkF https://t.co/ISuae2hCI3

• A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Syst…

Abst 0281 England & colleagues used unsupervised ML to determine whether peripheral biomarkers can accurately identify RA-ILD in large RA cohort - Identified 8 unique groups based on biomarkers - RF, anti-CCP, and -MAA biomarkers most closely associated w/ ILD https://t.co/831tP4JSh0